
Biopharma leader advancing therapies in virology, oncology and inflammation
Kite Pharma, under Gilead, markets approved autologous CAR-T therapies with strong clinical outcomes in blood cancers. High cost and ex vivo processing differentiate it from Kernal’s in vivo, lower-cost vision backed by ARPA-H.
Free